

## **Original Research Article**

### **Anti-Hyperglycemic and Anti-Hyperlipidemic Potentials of Methanol Leaf Extracts of Aframomum Melegueta and Piper Guineense**

Aim: The study investigated the anti-hyperglycemic and anti-hyperlipidemic potentials of methanol extracts of **Piper guineense** (PG) and **Aframomum melegueta** (AM) leaves with a view to utilizing the plants in the treatment and management of cardiovascular disorders.

Comment [W1]: Plant name should be in Italic

Comment [W2]: Italic

Methodology: Twenty-eight healthy albino rats were randomly divided into seven equal groups: Group I received normal saline (2 ml/kg bwt); Group II received a single dose of alloxan(150 mg/kg bwt) intraperitoneally; Group III received alloxan (150 mg/kg bwt) + glibenclamide(5 mg/kg bwt);Group IV received alloxan (150 mg/kg bwt) +PG (200 mg/kg bwt); Group V received alloxan (150 mg/kg bwt) + PG (400 mg/kg bwt); Group VI received alloxan (150 mg/kg bwt) + AM 200 (mg/kg bwt); Group VII received alloxan (150 mg/kg bwt) + AM (400 mg/kg bwt). The blood glucose level was determined before and after treatment with the extracts. **The lipid profiles:** (total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were estimated using the Randox diagnostic kits.

Comment [W3]: Remove

Results: The results revealed that alloxan was able to induce hyperglycemia at 150 mg/kg bwt and post-treatment with PG and AM at 200 mg/kg and 400 mg/ kg bwt were able to significantly lower the blood glucose level which was quite apparent in AM treated groups. Also, the extracts at 200 mg/kg and 400 mg/kg were able to bring a significant ( $p < 0.05$ ) reduction in TC, TG and LDL concentrations when compared to the alloxan treated group with the highest reduction in AM treated groups.

Conclusion: These results revealed that the methanol extract of AM and PG elicited anti-hyperglycemic and anti-hyperlipidemic potentials of the extracts with the highest effect in AM treated rats.

**Keywords:-** Anti-hyperglycemic, Anti-hyperlipidemic, **Piper guineense** (PG) and **Aframomum melegueta**

Comment [W4]: Italic

Comment [W5]: Italic

## 30 1. INTRODUCTION

31 *Diabetes mellitus* (DM) is a chronic metabolic disorder and is becoming a global health concern because  
32 of the increase in its prevalence. However, hyperglycemia and hyperlipidemia are some of the factors  
33 indicating this metabolic syndrome [1]. Hyperglycemia is a condition in which an excessive amount of  
34 [glucose](#) circulates in the [blood plasma](#). [Diabetic neuropathy](#) may be a result of long-term hyperglycemia.  
35 Hyperlipidemia is characterized by abnormal elevation in plasma triglyceride, cholesterol and low density  
36 lipoprotein-cholesterol (LDL-c) and very low lipoprotein - cholesterol (VLDL-c) and has also been  
37 reported to be the most prevalent indicator for susceptibility to atherosclerotic heart disease [2]. Also,  
38 high blood glucose levels are associated with low level of high-density lipoprotein cholesterol (HDL-c)  
39 and increase of [low-density lipoprotein cholesterol](#), thus increasing risk of coronary heart diseases.  
40 Therefore, it is vital to manage both diabetes and lipid levels [3]

Comment [W6]: Remove the hyperlink

Comment [W7]: Remove the hyperlink

Comment [W8]: Replace with "LDL-c"

41 The increase in demand for cheaper therapeutics with no/minimum side effects is stimulating interest in  
42 studying the use of natural products for the treatment and management of diseases [4, 5]. The medicinal  
43 values of these plants are usually due to the presence of phytochemicals [6, 7, 8].

44 *Piper guineense* is a spice which belongs to the family Piperaceae commonly known as West African  
45 Black Pepper. It is a climbing plant climbing up to 12m high by its adventitious rootlets. It is known with  
46 different vernacular names in Nigeria which include 'Uziza' in Igbo, and 'Iyere' in Yoruba. The seeds are  
47 smooth and are prolate-elliptically shaped. The seeds, leaves and sometimes the stems are used in  
48 preparing soup. It imparts "heat" and a spicy pungent aroma to food [9]. The plant is utilized for a variety  
49 of purposes which include human dietaries, preservative, bio-control agent as well as traditional medicine  
50 [9].

51 Previous phytochemical studies of *P. guineense* seed extract revealed the presence of various substances  
52 such as alkaloids, flavonoids, [tannis](#), [triterpenoids](#), [cardiac glycosides](#) and [saponins](#) [10]. Pharmacological  
53 and physiological studies of *P. guineense* extract showed depolarizing neuromuscular blocking action,  
54 insecticidal properties, sexual behavioural effect and antifungal activity [11] and edema in gastrointestinal  
55 tract, urinary bladder and adrenal glands and immunotoxicological effects [12].

Comment [W9]: Tannins,

56 *Aframomum melegueta* K. Schum belongs to the ginger family (Zingiberaceae) and it is commonly known  
57 as grains of paradise or alligator pepper [13]. It is variously known locally as *ose oji* in Igbo, *ataare* in  
58 Yoruba, and *cittáá* in Hausa of Nigeria. The seeds of *A. melegueta* have been variously reported to be rich  
59 in carbohydrates, crude fibre, and bulk minerals [14, 5, 15] suggesting it to be of good nutritional quality,  
60 and hence justifying its incorporation into diet. The report of [16, 17], NMR and GC-MS analyses of the  
61 chloroform extract of the seeds and essential oils from various plant parts, respectively show the plant to

62 be rich in secondary metabolites such as modified gingerols, paradols and shogaols. These metabolites  
63 account for some of peppery taste of the seeds [18]. The use of *A. melegueta* in traditional medicine in  
64 treating diabetes has been age long.

65 This study investigated the anti-hyperglycemia and lipid lowering effects of the leaf extracts of AM and  
66 PM.

## 67 2. MATERIALS AND METHODS

### 68 2.1 Chemicals

69 All chemicals and drugs used were obtained commercially and of analytical grade.

#### 70 2.1.1 Collection of plant materials

71 The leaves of *Aframomum melegueta* and *Piper guineense* were collected in February, 2015 at Okuku,  
72 Odo-Otin local government, Osun State, Nigeria. It was identified at IFE herbarium, Obafemi Awolowo  
73 University, Ile- Ife.

74 The methanolic extracts of *A. melegueta* and *P. guineense* were separately prepared. The leaves were  
75 dried under shade and ground into powder. Typically, the powder (200g) was macerated in 2.5 L  
76 methanol (70%) at room temperature for 72h. It was then filtered using muslin cloth. The filtrates were  
77 allowed to settle, decanted and filtered using filtration assembly. The filtrates were evaporated to dryness  
78 using rotary evaporator. The extracts were in air tight container in a refrigerator until used.

#### 79 2.2 Experimental Animals

80 Adult female and male albino rats (28) weighing between 120-150 g were obtained from the Animal  
81 House, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife. The rats were housed in polyethylene  
82 cages at the Animal House, Department of Biochemistry, Adeleke University, Ede and were kept under  
83 standard conditions; food and water were supplied *ad libitum*. They were allowed to acclimatized for a  
84 period of 14 days.

#### 85 2.3 Grouping and Treatment of Animals

86 The rats were randomly assigned into seven groups of four rats in each group as follows:

87 Group I: Control (Normal saline)

88 Group II: Alloxan Treated (150 mg/kg bwt)

89 Group III: Alloxan + Gilbenclamide (5mg/kg bwt)

90 Group IV: Alloxan + PG (200 mg/kg bwt)

Comment [W10]: Remove underline

Comment [W11]: Mention the specimen number.

Comment [W12]: Were stored

Comment [W13]: Whether the study was approved by Institutional Animal Ethical Committee clearance? If yes, mention the approval number.

Comment [W14]: Four rats per group is not sufficient. At least 6 animals/group should be taken

Comment [W15]: How the dose was arrived as 200 mg & 400 mg? If any literature support is there, mention it.

91 Group V: Alloxan + PG (400 mg/kg bwt)

92 Group VI: Alloxan + AM (200 mg/kg bwt)

93 Group VII: Alloxan + AM (400 mg/kg bwt)

94 The extracts and the reference drug (Glibenclamide) were administered orally.

**Comment [W16]:** How the dose was arrived as 200 mg & 400 mg? If any literature support is there, mention it.

**Comment [W17]:** Glibenclamide

**Comment [W18]:** administered

## 95 2.4 Induction of *Diabetes* and Treatment with the Extracts

96 The animals were allowed to fast overnight and diabetes was induced by a single intra-peritoneal injection  
97 of alloxan monohydrate (150 mg/kg bwt). Increase glucose level was monitored 3 days after injection by  
98 measuring the tail vein blood glucose level using glucometer. The induced rats were orally treated with  
99 the extracts for 7 days.

## 100 2.5 Determination of Blood Glucose Levels

101 The level of blood glucose was determined before and after treatment with the extract and standard drug  
102 by using a glucometer. The rats were subjected to fasting for 12-18 h with free access to water prior to the  
103 administration of the extract and the blood glucose level was measured [19]. After the last treatment with  
104 the extracts, the animals were fasted overnight and the blood samples were collected for the determination  
105 of the blood glucose concentration.

## 106 2.6 Sacrificing and Preparation of Blood Plasma

107 The rats were sacrificed under mild anaesthesia with ether, twenty four hours after the last treatment (oral  
108 administration of extracts and drug). Blood was collected by cardiac puncture into bottles containing  
109 anticoagulant (trisodium citrate, 3.8% w/v) and mixed gently. Blood plasma was prepared using standard  
110 procedure as reported and modified by Bode and Oyedapo [20]. Blood sample was centrifuged on Bench  
111 Centrifuge Model 90-2 (Searchtech Instrument England, UK.) at 3000 rpm for 10 min. The supernatant  
112 (plasma) was collected into sterile bottles, labeled and stored in freezer for biochemical analyses.

**Comment [W19]:** 24 h

## 113 2.7 Estimation of Plasma Lipid Profiles

114 Plasma lipid profiles: triacylglycerol (TG), total cholesterol (TC), High density lipoprotein cholesterol  
115 (HDL-c), low density lipoprotein cholesterol (LDL-c), were estimated spectrophotometrically using  
116 Randox assay kits.

## 117 2.8 Statistical analysis

118 The data were statistically analyzed using t-test and ANOVA with the aid of SAS software package. The  
119 level of statistical significance was also compared using Duncan's multiple range test  $p < 0.05$ .

## 120 3. RESULTS

121 **3.1 Blood Glucose Level**

122 In Table 1 is the summary of the initial and final concentrations of blood glucose. After induction of  
 123 hyperglycemia with alloxan monohydrate, there was a significant increase ( $P < 0.05$ ) in blood glucose level  
 124 of other experimental groups when compared with the normal control group. After treatment the extracts  
 125 at 200 mg/kg and 400 mg/kg, the blood glucose level was significantly reduced ( $P < 0.05$ ) when compared  
 126 to the alloxan treated rats. This indicated the anti-hyperglycemic potentials of the extracts.

127

128 **Table 1: Effects of Methanolic Extract of PG and AM on Blood Glucose Concentration (mg/dl) of**  
 129 **Alloxan-induced Hyperglycemic Rats**

Treatment Group	Initial Blood Glucose (mg/dl)	Final Blood Glucose (mg/dl)	% Change
Control	80.50 ± 2.02 <sup>a</sup>	75.75 ± 1.11 <sup>e</sup>	5.90
Alloxan Treated	79.25 ± 0.85 <sup>b</sup>	199.00 ± 1.68 <sup>a</sup>	151.10
Alloxan + Gilbenclamide (5mg/kg bwt)	59.25 ± 0.48 <sup>d</sup>	95.75 ± 0.85 <sup>d</sup>	61.60
Alloxan + PG (200 mg/kg bwt)	68.25 ± 0.35 <sup>c</sup>	137.75 ± 2.66 <sup>b</sup>	101.83
Alloxan + PG (400 mg/kg bwt)	75.50 ± 1.09 <sup>b</sup>	114.50 ± 3.07 <sup>c</sup>	51.66
Alloxan + AM (200 mg/kg bwt)	79.50 ± 0.87 <sup>b</sup>	65.50 ± 1.96 <sup>d</sup>	-17.61
Alloxan + AM (400 mg/kg bwt)	74.25 ± 0.91 <sup>b</sup>	72.25 ± 1.58 <sup>d</sup>	2.69

Comment [W20]: Initial

130

131 Each value represented mean ± SEM,  $n = 5$  readings. Values with different superscript  
 132 alphabet are significantly different at  $P < 0.05$ .

Comment [W21]: Not clear

Comment [W22]: The level of significance should be indicated. The superscripts are poorly explained.

133 **3.2 Lipid Profiles**

134 In Table 2 is the summary of the effect of the extracts on the plasma lipid profile of alloxan-induced  
 135 hyperglycemia rats. There was significant increase in the concentrations of TC, TG and LDL-c but a  
 136 decrease in HDL-c of the alloxan treated group when compared to the control group. However, treatment  
 137 with the extracts at 200 and 400 mg/kg bwt caused a significant reduction in the concentrations of TC, TG  
 138 and LDL-c but an increase in HDL-c.

Comment [W23]: profiles

139

140

141

142 **Table 2: The effects of methanolic extract of *Piper guineense* on lipid profile (mmol/L) of alloxan-**  
 143 **induced hyperglycemic rats.**

Treatment Group	TC	TG	HDL	LDL
Control	5.99 ± 0.003 <sup>c</sup>	1.61 ± 0.001 <sup>d</sup>	4.54 ± 0.001 <sup>a</sup>	0.714 ± 0.008 <sup>c</sup>
Alloxan Treated	15.82 ± 0.019 <sup>a</sup>	4.89 ± 0.002 <sup>a</sup>	0.02 ± 0.001 <sup>c</sup>	13.58 ± 0.019 <sup>a</sup>
Alloxan + Gilbenclamide (5mg/kg bwt)	8.253 ± 0.019 <sup>c</sup>	1.96 ± 0.310 <sup>c</sup>	3.27 ± 0.019 <sup>c</sup>	4.09 ± 0.014 <sup>c</sup>
Alloxan + PG (200 mg/kg bwt)	9.448±0.102 <sup>b</sup>	3.862±0.021 <sup>b</sup>	2.266±0.387 <sup>d</sup>	5.426±0.061 <sup>b</sup>
Alloxan + PG (400 mg/kg bwt)	7.318±0.018 <sup>d</sup>	2.008±0.003 <sup>c</sup>	4.364±0.017 <sup>b</sup>	5.426±0.061 <sup>b</sup>
Alloxan + AM (200 mg/kg bwt)	9.35 ± 0.046 <sup>a,c</sup>	0.961 ± 0.032 <sup>bc</sup>	6.95 ± 0.04 <sup>a</sup>	1.05 ± 0.10 <sup>b,c</sup>
Alloxan + AM (400 mg/kg bwt)	8.411 ± 0.062 <sup>ac</sup>	2.381 ± 0.02	7.12 ± 0.002 <sup>a</sup>	0.214 ± 0.07 <sup>d</sup>

Comment [W24]: Units should be mentioned

144

145 Values are mean ± SEM of five determinations. Values with different superscript alphabet are  
 146 significantly different at P<0.05.

Comment [W25]: How it comes to five determinations? Number of animals takes per group is only four.

147 **4. Discussion**

Comment [W26]: Poor statistical analysis. The level of significance is poorly analysed and expressed.

148 The study evaluated anti-hyperglycemia and lipid-lowering effect of *A. melegueta* and *P. guineense* leaf  
 149 extracts. After the administration of alloxan monohydrate, there was significant increase (p < 0.05) in the  
 150 blood glucose level of the negative control group when compared to the normal control group (Table  
 151 1). Elevated value of fasting blood glucose concentration observed in alloxan treated rats may be due to  
 152 the toxic effect of alloxan on islet beta cells of the pancreas through its ability to induce reactive oxygen  
 153 species (ROS) formation, resulting in the necrosis of the pancreas and loss of capacity of the pancreas to  
 154 secrete insulin resulting to hyperglycemia [21, 22, 23].

155 Chronic exposure to hyperglycemia is the primary casual factor in the pathogenesis of diabetic  
 156 complications and cause changes in vascular tissue which promote atherosclerosis [24]. Our findings is in  
 157 agreement with the report of earlier studies that administration of alloxan at the dose of 250mg/kg was  
 158 able to increase to elevate the fasting blood sugar levels [19, 24]. Post-treatments with 200 mg/kg and 400  
 159 mg/ kg PG and AM extracts were able to significantly lower the blood glucose respectively when  
 160 compared to the alloxan treated group.

161 Both extracts compared favorably with the reference drug, **Glibenclamide** and the highest effect was  
162 observed in *A. Melegueta* at 200 mg/kg bwt. The observed anti-hyperglycemia activity of these extracts  
163 may be attributed to the presence of bioactive compounds such as flavonoids in the extract. It is well  
164 documented that hypoglycemic activities of many medicinal plants are attributed to the presence of  
165 phenolic compounds and flavonoids [25]. Studies also reported that flavonoids have anti-hyperglycemic  
166 properties because they stimulate glucose uptake in peripheral tissues and attenuate oxidative stress  
167 during diabetic conditions [26,27].

**Comment [W27]:** Glibenclamide

168 One of the associated metabolic disorders of diabetes is dyslipidemia which is one of the risk factors of  
169 diabetes [28]. Hypercholesterolemia and hypertriglyceridemia have been reported to occur in alloxan  
170 treated rats [29, 30]. The elevated values for lipid profile TC, TG, LDL-cholesterol, observed in the  
171 alloxan induced diabetic rats could be partly due to increased intestinal biosynthesis of cholesterol  
172 because diabetes shifted the major site of cholesterologenesis from the liver to the small intestine leading to  
173 hypercholesterolemia [31]. Severe diabetes mellitus due to insulin deficiency might be accompanied with  
174 a reduced LDL-receptor resulting to high concentration of serum LDL cholesterol in diabetic subjects  
175 [32].

176  
177 The results of the extracts treated groups revealed a significant reduction in the levels of total cholesterol,  
178 triglyceride, LDL but an increase in HDL. The anti-hyperlipidemic effect was more apparent in the *A.*  
179 *melegueta* treated group at 200 and 400 mg/kg bwt. This revealed **anti-hyperlipidemic** of the plant  
180 extracts. The ability of the plant to ameliorate the lipid profile may be attributed to the presence of  
181 flavonoids in the plants. The presence of flavonoids in AM and PG was earlier reported by Echo et al.  
182 [33] and Fajobi et al. [34] Epidemiological studies have shown that flavonoids intake are inversely related  
183 to mortality from coronary heart diseases and the incidence of heart attacks [33]

**Comment [W28]:** Antihyperlipidemic activity

184 In conclusion, the results affirmed that the plant extracts elicited anti-hyperglycemic effect and  
185 normalized the lipid profile of diabetic rats. This study showed that these spices do not just impact flavour  
186 to foods, but may be sources of bioactive substances useful in the treatment and management of diabetes  
187 and related disorders.

188

189

190

191

192 **REFERENCES**

- 193 1. Deguchi Y, Miyazaki K. Anti-hyperglycaemic and anti-hyperlipidemic effects of guava leaf extract  
194 Nutrition and Metabolism 2010; 7: 1-10.
- 195 2. Maruthapan V, Shree K. Antihyperlipidemic potential of a polyherbal drug (Geriforte) on atherogenic  
196 diet induced hyperlipidemia: A Comparison with Ayurslim. International Journal of Chemical and  
197 Analytical Science 2010,3, 37-39
- 198 3. Sudasinghe HP, Peiris DC. Hypoglycemic and hypolipidemic activity of aqueous leaf extract of  
199 *Passiflora suberosa* L. PeerJ, 2018; 6:e4389; DOI 10.7717/peerj.4389
- 200 4. Sigh S. From exotic spice to modern drug? Cell 2007; 130: 765–768.
- 201 5. Dolui AK, Segupta R. Anti-hyperglycemic effect of different extracts of leaves of *Cajanus cajan*  
202 HPLC profile of the active extracts Asian Journal of Pharmaceutical and Clinical Research 2012; 5:116–  
203 119.
- 204 6. Poongothai A, Sreena, KP, Sreejith K, Uthiralingam M, Annapoorani S. Preliminary phytochemicals  
205 screening of *Ficus racemosa* linn. bark. International Journal of Pharmaceuticals and Biological Sciences  
206 2011; 2(2): 431-434.
- 207 7. Essien EB, Onyeike EN, Ugheyide DE, Eneke IC. Effect of aqueous extract of *Occimum basilicum*  
208 leaves on some hematological and biochemical parameters of Wister albino rats. Canadian Journal on  
209 Scientific and Industrial Research 2012; 3: 256-264.
- 210 8. Etim OE, Egbuna CF, Odo NM, Awah, FM. In vitro antioxidant and nitric oxide scavenging activities  
211 of *Piper guineense*. Global Journal of Research in Medical Plants and Indigenous Medicine 2013; 2: 485–  
212 494.
- 213 9. Martins AP, Salgueiro L, Vila R, Tomi F, Canigüeral S, Casanova J, Proença DA, Cunha A, Adzet T.  
214 Essential oils from four *Piper* Species. Phytochem. 1558, 49, 2019-2023.
- 215 10. Fajobi OA, Fasakin OW, Oyedapo, OO. 2017. Phytochemicals, Antioxidant Potentials, and 2, 2'-  
216 diphenyl-1-picryldrazyl (DPPH) Radical Scavenging Activity of *Piper guineense* (Schumach &  
217 Thonn.) Seed. African Journal of Plant Science 2017; 11: 99-104.
- 218 11. Adewoyin FB, Odaibo AB, Adewunmi CO. Mosquito repellent activity of *Piper guineense* and  
219 *Xylopiya aethiopica* fruit oils. Afr. J. Trad. Compl. Alter. Med., 2006; 3(2): 79-83.
- 220 12. Daware MB, Mujumdar AM, Ghaskadbi S. Reproductive toxicity of piperine in Swiss albino  
221 mice Planta Med. 2000; 66:231-236.
- 222 13. Nwaehujor CO, Eban LK Ode JO, Ejiofor CE, Igile GO. Hepatotoxicity of methanol seed extract of  
223 *Aframomum melegueta* [Roscoe] K. Schum. (Grains of paradise) in Sprague-Dawley rats American  
224 Journal of Biomedical Research 2014; 2: 61–66.

**Comment [W29]:** References should be formatted according to the journal guidelines. All the references should be formatted and it should be uniform. The authors are insisted to strictly adhere the guideline given by the journal.



225 14. Dike, MC, Ahamefula NE. Comparative study of proximate, phytochemical and mineral  
226 compositions of edible plant fruits/seeds from Nigerian rainforest International Journal of Biology and  
227 Chemical Sciences 2012; 6; 1905–1909.

228 15. Alaje DO, Owolabi KT, Olakunle TP, Oluoti OJ, Adetuberu IA. Nutritional, minerals and  
229 phytochemicals composition of *Garcinia cola* [Bitter cola] and *Aframomum melegueta* (Alligator pepper)  
230 IOSR Journal of Environmental Science, Toxicology And Food Technology (IOSR-JESTFT) 2014; 8:  
231 86–91.

232 16. Owokotomo IA, Ekundayo O, Oguntuase BJ. Chemical constituents of the leaf, stem, root and seed  
233 essential oils of *Aframomum melegueta* (K. Schum) from South West Nigeria. International Research  
234 Journal of Pure and Applied Chemistry 2013; 4: 395–401.

235 17. El-Halawany AM, El-Dine RS, El-Sayed NS, Hattor I. M. Protective effect of *Aframomum melegueta*  
236 phenolics against CCl<sub>4</sub>-induced rat hepatocytes damage; role of apoptosis and pro-inflammatory cytokines  
237 inhibition Science Reports 2014; 30: 5880.

238 18. Ajaiyeoba EO, Ekundayo O. Essential oil constituents of *Aframomum melegueta* (Roscoe) K. Schum  
239 seeds (alligator pepper) from Nigeria Flavour and Fragrance Journal 2009; 14: 109–111.

240 19. Mojekwu TO, Yama OE, Ojokuku SA, Oyebadejo SA. Hypoglycaemic effects of aqueous extract of  
241 *Aframomum melegueta* leaf on alloxan-induced diabetic male albino rats Pacific Journal of Medical  
242 Sciences 2011; 8: 28 – 36

243 20. Bode SO, Oyedapo OO. Biological activities and phytoconstituents of the lower plant *Platyserium*  
244 *angolense*, Welwex Hook Journal of Medicinal Plants Research 2011; 5: 1321-1329.

245 21. Ohno T, Horio F, Tanaka S, Terada M, Namikawa TA. Fatty liver and hyperlipidemia in IDDM  
246 (insulin dependent diabetes mellitus) of Streptozotocin treated shrews Journal of Life Science 2000;  
247 66(2):125-131.

248 22. Lenzen S. Review: The mechanisms of alloxan- and streptozotocin-induced diabetes Diabetologia  
249 2008; 51: 216–226.

250 23. Zafar M, Naeem-Ul H, Aaqvi A, Ahmed A. Altered liver morphology and enzymes in streptozotocin  
251 induced diabetic rats International Journal of Morphology 2009; 23: 719-725.

252 24. [Badin JK](#), [Kole A](#), [Stivers B](#), [Progar V](#), [Pareddy A](#), [Alloosh M](#), [Sturek M](#). Diabetes Exacerbates  
253 Coronary Atherosclerosis in Ossabaw Miniature Swine with Metabolic Syndrome [J. Transl. Med.](#) 2018;  
254 16(1): 58.

255 25. Romano B, Pagano E, Montanaro V, Fortunato AL, Milic N, Borrelli F. Novel insights into the  
256 pharmacology of flavonoids *Phytother Res.* 2013, 27(11), 1588-1596.

257 26. Eid HM, Martineau LC, Saleem A, Muhammad A, Vallerand D. Benhaddou-Andaloussi, A.  
258 Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by

259 quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant *Vaccinium vitis-*  
260 *idaea* Mol. Nutr. Food Res. 2010; 54(7): 991-1003.

261 27. Rauter AP, Martins A, Borges C, Mota-Filipe H, Pinto R, Sepodes B. Anti-hyperglycaemic and  
262 protective effects of flavonoids on streptozotocin-induced diabetic rats Phytother Res. 2010; 24: S133-  
263 138

264 28. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence,  
265 pathophysiology, and management Drugs 2013; 73(4): 327-339.

266 29. Wang L, Zhang XT, Zhang HY, Yao HY, Zhang H. Effect of *Vaccinium bracteatum* Thunb. leaves  
267 extract on blood glucose and plasma lipid levels in streptozotocin-induced diabetic mice J.  
268 Ethnopharmacol. 2010; 130(3): 465-9.

269 30. Balamurugan R, Ignacimuthu, S. Antidiabetic and hypolipidemic effect of methanol extract of *Lippia*  
270 *nodiflora* L. in streptozotocin induced diabetic rats Asian Pac J Trop Biomed 2011;1: S30-36.

271 31. Luka C, Tijjani H, Joel E, Ezejiofor U, Onwukike P. Hypoglycaemic properties of aqueous extracts of  
272 *Anacardium occidentale*, *Moringa oleifera*, *Vernonia amygdalina* and *Helianthus annuus*: A comparative  
273 study on some biochemical parameters in diabetic rats International Journal of Pharmaceutical Science  
274 Invention 2013; 2: 16-22.

275 32. Swami S, Sztalryd C, Kraemer FB. Effects of streptozotocin-induced diabetes on low density  
276 lipoprotein receptor expression in rat adipose tissue Journal of Lipid Research 1996; 37: 229-239.

277 33. Echo IA, Osuagwu AN, Agbor RB, Okaka EC, Ekanem BE. Phytochemical composition of  
278 *Aframomum melegueta* and *Piper guineense* seeds World Journal of Applied Environmental Chemistry  
279 2012; 2:17-21.

280